vs
Side-by-side financial comparison of Boston Scientific (BSX) and GE HealthCare (GEHC). Click either name above to swap in a different company.
GE HealthCare is the larger business by last-quarter revenue ($5.7B vs $5.2B, roughly 1.1× Boston Scientific). Boston Scientific runs the higher net margin — 25.7% vs 10.3%, a 15.4% gap on every dollar of revenue. On growth, Boston Scientific posted the faster year-over-year revenue change (11.6% vs 7.1%). Over the past eight quarters, Boston Scientific's revenue compounded faster (12.4% CAGR vs 10.7%).
Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
GE Healthcare Technologies, Inc., stylized GE HealthCare, is an American health technology company based in Chicago, Illinois. It operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical Diagnostics, which manufactures...
BSX vs GEHC — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.2B | $5.7B |
| Net Profit | $1.3B | $588.0M |
| Gross Margin | 69.5% | 39.7% |
| Operating Margin | — | 14.5% |
| Net Margin | 25.7% | 10.3% |
| Revenue YoY | 11.6% | 7.1% |
| Net Profit YoY | 99.0% | -18.4% |
| EPS (diluted) | $0.90 | $1.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $5.2B | — | ||
| Q4 25 | $5.3B | $5.7B | ||
| Q3 25 | $5.1B | $5.1B | ||
| Q2 25 | $5.1B | $5.0B | ||
| Q1 25 | $4.7B | $4.8B | ||
| Q4 24 | $4.6B | $5.3B | ||
| Q3 24 | $4.2B | $4.9B | ||
| Q2 24 | $4.1B | $4.8B |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $670.0M | $588.0M | ||
| Q3 25 | $755.0M | $446.0M | ||
| Q2 25 | $795.0M | $486.0M | ||
| Q1 25 | $672.0M | $564.0M | ||
| Q4 24 | $563.0M | $721.0M | ||
| Q3 24 | $468.0M | $470.0M | ||
| Q2 24 | $322.0M | $428.0M |
| Q1 26 | 69.5% | — | ||
| Q4 25 | 69.6% | 39.7% | ||
| Q3 25 | 69.9% | 38.7% | ||
| Q2 25 | 67.7% | 39.6% | ||
| Q1 25 | 68.8% | 42.1% | ||
| Q4 24 | 67.8% | 42.8% | ||
| Q3 24 | 68.8% | 41.7% | ||
| Q2 24 | 69.2% | 41.4% |
| Q1 26 | — | — | ||
| Q4 25 | 15.6% | 14.5% | ||
| Q3 25 | 20.7% | 12.7% | ||
| Q2 25 | 16.2% | 13.1% | ||
| Q1 25 | 19.8% | 13.2% | ||
| Q4 24 | 14.8% | 15.1% | ||
| Q3 24 | 17.4% | 13.9% | ||
| Q2 24 | 12.6% | 12.6% |
| Q1 26 | 25.7% | — | ||
| Q4 25 | 12.7% | 10.3% | ||
| Q3 25 | 14.9% | 8.7% | ||
| Q2 25 | 15.7% | 9.7% | ||
| Q1 25 | 14.4% | 11.8% | ||
| Q4 24 | 12.3% | 13.6% | ||
| Q3 24 | 11.1% | 9.7% | ||
| Q2 24 | 7.8% | 8.8% |
| Q1 26 | $0.90 | — | ||
| Q4 25 | $0.45 | $1.28 | ||
| Q3 25 | $0.51 | $0.98 | ||
| Q2 25 | $0.53 | $1.06 | ||
| Q1 25 | $0.45 | $1.23 | ||
| Q4 24 | $0.38 | $1.58 | ||
| Q3 24 | $0.32 | $1.02 | ||
| Q2 24 | $0.22 | $0.93 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $4.5B |
| Total DebtLower is stronger | — | $10.0B |
| Stockholders' EquityBook value | — | $10.4B |
| Total Assets | — | $36.9B |
| Debt / EquityLower = less leverage | — | 0.96× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $2.0B | $4.5B | ||
| Q3 25 | $1.3B | $4.0B | ||
| Q2 25 | $534.0M | $3.7B | ||
| Q1 25 | $725.0M | $2.5B | ||
| Q4 24 | $414.0M | $2.9B | ||
| Q3 24 | $2.5B | $3.5B | ||
| Q2 24 | $2.9B | $2.0B |
| Q1 26 | — | — | ||
| Q4 25 | $11.1B | $10.0B | ||
| Q3 25 | $11.1B | $10.3B | ||
| Q2 25 | $11.1B | $10.3B | ||
| Q1 25 | $10.5B | $8.8B | ||
| Q4 24 | $9.0B | $9.0B | ||
| Q3 24 | $9.2B | $10.3B | ||
| Q2 24 | $9.0B | $9.2B |
| Q1 26 | — | — | ||
| Q4 25 | $24.2B | $10.4B | ||
| Q3 25 | $23.4B | $10.0B | ||
| Q2 25 | $22.4B | $9.7B | ||
| Q1 25 | $22.2B | $9.2B | ||
| Q4 24 | $21.8B | $8.4B | ||
| Q3 24 | $20.7B | $8.3B | ||
| Q2 24 | $20.4B | $7.8B |
| Q1 26 | — | — | ||
| Q4 25 | $43.7B | $36.9B | ||
| Q3 25 | $42.7B | $36.1B | ||
| Q2 25 | $41.6B | $35.5B | ||
| Q1 25 | $40.1B | $33.6B | ||
| Q4 24 | $39.4B | $33.1B | ||
| Q3 24 | $38.1B | $33.9B | ||
| Q2 24 | $37.1B | $31.9B |
| Q1 26 | — | — | ||
| Q4 25 | 0.46× | 0.96× | ||
| Q3 25 | 0.48× | 1.03× | ||
| Q2 25 | 0.50× | 1.06× | ||
| Q1 25 | 0.47× | 0.95× | ||
| Q4 24 | 0.41× | 1.06× | ||
| Q3 24 | 0.45× | 1.24× | ||
| Q2 24 | 0.44× | 1.18× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BSX
| Cardiovascular | $3.1B | 59% |
| Endoscopy | $673.0M | 13% |
| Urology | $633.0M | 12% |
| Other | $386.0M | 7% |
| Neuromodulation | $271.0M | 5% |
| LACA | $155.0M | 3% |
GEHC
| Imaging Segment | $2.6B | 45% |
| PCS Segment | $824.0M | 14% |
| P Dx Segment | $790.0M | 14% |
| Specialized Ultrasound Subsegment | $735.0M | 13% |
| Monitoring Solutions Subsegment | $578.0M | 10% |
| Life Support Solutions Subsegment | $247.0M | 4% |
